Financial Performance - Total revenue for the three months ended March 31, 2025, was 2,220million,a12,190 million in the same period of 2024, with operational revenue growth of 5%[100] - Net income attributable to Zoetis for the three months ended March 31, 2025, was 631million,reflectinga5599 million in the same period of 2024[112] - Adjusted net income for the same period was 662million,up4634 million in 2024[100] - U.S. segment revenue increased by 20million,or21,183 million in Q1 2025, driven by an increase in companion animal products[133] - International segment revenue was relatively flat, but operational revenue increased by 73million,or729 million, or 1%, to 2,220millioninQ12025comparedto2,190 million in Q1 2024[130] - Gross profit for the U.S. segment increased by 38million,or4984 million in Q1 2025, with a gross margin of 83.2%[132] - International segment earnings increased by 16million,or3551 million in Q1 2025, with operational earnings growth of 35million,or71.48, an increase of 7% compared to 1.38inQ12024[154]ExpensesandCosts−Costofsalesdecreasedto28.016 million, or 3%, to 563millioninQ12025comparedto547 million in Q1 2024[118] - Research and development expenses decreased by 5million,or3157 million in Q1 2025, attributed to timing of spend related to projects[119] - Amortization of intangible assets decreased to 32millioninQ12025from37 million in Q1 2024, primarily due to assets becoming fully amortized[120] - Interest expense, net of capitalized interest, decreased by 4million,or754 million in Q1 2025 compared to 58millioninQ12024[126]−Provisionfortaxesonincomeincreasedby21 million, or 14%, to 179millioninQ12025,withaneffectivetaxrateof22.117 million, or 6%, in Q1 2025, primarily due to favorable foreign exchange and lower compensation-related costs[140] Cash Flow and Liquidity - Net cash provided by operating activities decreased to 587millioninQ12025from595 million in Q1 2024, primarily due to timing of receipts and payments[164] - Net cash used in investing activities increased to 175millioninQ12025from131 million in Q1 2024, mainly due to capital expenditures[165] - Net cash used in financing activities rose to 677millioninQ12025from524 million in Q1 2024, driven by treasury share purchases and dividend payments[166] - As of March 31, 2025, cash and cash equivalents totaled 1,721million,downfrom1,987 million on December 31, 2024, indicating a decrease of approximately 13.4%[168] - The current ratio of current assets to current liabilities was 1.74:1 as of March 31, 2025, slightly down from 1.75:1 on December 31, 2024[168] - The company anticipates that global economic conditions may impact liquidity, but it believes it can meet liquidity needs for the foreseeable future due to operating cash flows and access to capital markets[173] Debt and Credit Facilities - The company has a multi-year 1.0billionseniorunsecuredrevolvingcreditfacility,whichcanbeincreasedto1.5 billion under certain conditions, expiring in December 2027[169] - As of March 31, 2025, the company had access to 51millionofadditionallinesofcredit,withnoborrowingsoutstandingrelatedtothesefacilities[171]−Thecompany’soutstandingdebtsecuritiesinclude750 million in 2015 Senior Notes due 2025 with a 4.500% interest rate and 600millionin2022SeniorNotesdue2025witha5.400443 million during the first three months of 2025, with 5.2billionremainingundertheauthorizedsharerepurchaseprogram[180]−Otherbusinessactivitiesnetlossdecreasedby3 million in Q1 2025, reflecting a decrease in R&D costs[139] - Total purchase accounting adjustments for Q1 2025 were 31million,downfrom35 million in Q1 2024[156] - Interest expense for Q1 2025 was 54million,adecreasefrom58 million in Q1 2024[155] - The company regularly monitors accounts receivable, which were collected within the standard range of 45 to 75 days, with accounts receivable net totaling $1,361 million as of March 31, 2025[168] Market Presence - Zoetis operates in approximately 45 countries and is a market leader in nearly all major regions, with a diversified product portfolio of around 300 product lines[97]